Baseline characteristics of men undergoing benign prostatic enlargement (BPE) surgery from 2003 to 2014 in Ontario, Canada
| Total cohort | ||
| Variable | n=52 162 | |
| Mean age (years; SD) | 75.76 | ±6.41 |
| Intervention type (N, %) | ||
| TURP | 45 463 | 87.2% |
| Laser | 5925 | 11.4% |
| Open | 774 | 1.5% |
| Preoperative urinary obstruction* (N, %) | 25 779 | 49.4% |
| 5ARI medication (only) in year prior to surgery (N, %) | 2378 | 4.6% |
| α-blocker medication (only) in year prior to surgery (N, %) | 20 600 | 39.5% |
| 5ARI and α-blocker in year prior to surgery (N, %) | 14 450 | 27.7% |
| No BPE medications prior to surgery (N, %) | 14 734 | 28.2% |
| Antithrombotic in year prior to surgery (N, %) | 12 837 | 24.6% |
| Charlson Comorbidity Index (N, %) | ||
| 0 | 40 694 | 78.0% |
| 1 | 3961 | 7.6% |
| 2+ | 7507 | 14.4% |
| Income quintile (N, %) | ||
| Missing | 167 | 0.3% |
| 1 | 9553 | 18.3% |
| 2 | 10 728 | 20.6% |
| 3 | 10 263 | 19.7% |
| 4 | 10 689 | 20.5% |
| 5 | 10 762 | 20.6% |
| Rural residence (N, %) | 7264 | 13.9% |
*Preoperative urinary obstruction events include: urinary retention, bladder neck obstruction or obstructive uropathy.
ARI, α-reductase inhibitor; TURP, Transurethral resection of the prostate.